ArticleCirculation. Heart failure2017
Progenitor Cells and Clinical Outcomes in Patients With Heart Failure.
Open access · bronzeAbstract read
In one paragraph
Article in Circulation. Heart failure, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 49 citations in OpenAlex.
- A pilot clinical trial of cell therapy in heart failure with preserved ejection fraction.European journal of heart failure · 2022Trial
- Endothelial progenitor cells mobilization after maximal exercise according to heart failure severity.World journal of cardiology · 2020Trial
- The impact of patient sex on the response to intramyocardial mesenchymal stem cell administration in patients with non-ischaemic dilated cardiomyopathy.Cardiovascular research · 2020Trial
- CAR-CD34 (+) hematopoietic stem/progenitor cells produced in vivo protect against thoracic aortic aneurysm and dissection.Nature communications · 2026Article
- Biomarkers in Heart Failure: A Review and a Wish.International journal of molecular sciences · 2025Review
- Circulating Progenitor Cells and Coronary Collaterals in Chronic Total Occlusion.International journal of cardiology · 2024Article
- Vitamin D Deficiency, Inflammation, and Diminished Endogenous Regenerative Capacity in Coronary Heart Disease.JACC. Advances · 2024Article
- Effects of Exercise Training on Circulating Biomarkers of Endothelial Function in Pulmonary Arterial Hypertension.Biomedicines · 2023Article
- Maximal Exercise Improves the Levels of Endothelial Progenitor Cells in Heart Failure Patients.Current issues in molecular biology · 2023Article
- Circulating progenitor cells and outcomes in patients with coronary artery disease.International journal of cardiology · 2023Article
- Review
- The association between baseline circulating progenitor cells and vascular function: The role of aging and risk factors.Vascular medicine (London, England) · 2022Article
- Exercise Training Effects on Circulating Endothelial and Progenitor Cells in Heart Failure.Journal of cardiovascular development and disease · 2022Review
- Endothelial Progenitor Cell Response to Acute Multicomponent Exercise Sessions with Different Durations.Biology · 2022Article
- Endothelial-Mesenchymal Transition or Functional Tissue Regeneration - Two Outcomes of Heart Remodeling.Physiological research · 2021Review
- Endothelial Progenitor Cells: An Appraisal of Relevant Data from Bench to Bedside.International journal of molecular sciences · 2021Review
- Exercise training in heart transplantation.World journal of transplantation · 2021Review
- Type 1 diabetes patients increase CXCR4Scientific reports · 2021Article
- The prevalence, predictors, and outcomes of spontaneous echocardiographic contrast or left ventricular thrombus in patients with HFrEF.ESC heart failure · 2021Article
- A novel risk model to predict first-ever ischemic stroke in heart failure with reduced ejection fraction.Aging · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 1 institution in 2 countries.
Ayman Samman TahhanFrom the Division of Cardiology, Emory University School of Medicine, Atlanta, GA (A.S.T., M.H., P.B.S., S.S.H., A.P.K., A.A., H.M.-K., M.T., N.G., K.C., H.A., I.H., J.H.K., P.W., L.S., V.V., A.A.Q.); and Department of Biostatistics and Bioinformatics (Y.-A.K., E.M.) and Department of Hematology and Oncology, Winship Cancer Institute (E.K.W.), Emory University, Atlanta, GA.
Muhammad HammadahFrom the Division of Cardiology, Emory University School of Medicine, Atlanta, GA (A.S.T., M.H., P.B.S., S.S.H., A.P.K., A.A., H.M.-K., M.T., N.G., K.C., H.A., I.H., J.H.K., P.W., L.S., V.V., A.A.Q.); and Department of Biostatistics and Bioinformatics (Y.-A.K., E.M.) and Department of Hematology and Oncology, Winship Cancer Institute (E.K.W.), Emory University, Atlanta, GA.
Pratik B SandesaraFrom the Division of Cardiology, Emory University School of Medicine, Atlanta, GA (A.S.T., M.H., P.B.S., S.S.H., A.P.K., A.A., H.M.-K., M.T., N.G., K.C., H.A., I.H., J.H.K., P.W., L.S., V.V., A.A.Q.); and Department of Biostatistics and Bioinformatics (Y.-A.K., E.M.) and Department of Hematology and Oncology, Winship Cancer Institute (E.K.W.), Emory University, Atlanta, GA.
Salim S HayekFrom the Division of Cardiology, Emory University School of Medicine, Atlanta, GA (A.S.T., M.H., P.B.S., S.S.H., A.P.K., A.A., H.M.-K., M.T., N.G., K.C., H.A., I.H., J.H.K., P.W., L.S., V.V., A.A.Q.); and Department of Biostatistics and Bioinformatics (Y.-A.K., E.M.) and Department of Hematology and Oncology, Winship Cancer Institute (E.K.W.), Emory University, Atlanta, GA.
Andreas P KalogeropoulosFrom the Division of Cardiology, Emory University School of Medicine, Atlanta, GA (A.S.T., M.H., P.B.S., S.S.H., A.P.K., A.A., H.M.-K., M.T., N.G., K.C., H.A., I.H., J.H.K., P.W., L.S., V.V., A.A.Q.); and Department of Biostatistics and Bioinformatics (Y.-A.K., E.M.) and Department of Hematology and Oncology, Winship Cancer Institute (E.K.W.), Emory University, Atlanta, GA.
Ayman AlkhoderFrom the Division of Cardiology, Emory University School of Medicine, Atlanta, GA (A.S.T., M.H., P.B.S., S.S.H., A.P.K., A.A., H.M.-K., M.T., N.G., K.C., H.A., I.H., J.H.K., P.W., L.S., V.V., A.A.Q.); and Department of Biostatistics and Bioinformatics (Y.-A.K., E.M.) and Department of Hematology and Oncology, Winship Cancer Institute (E.K.W.), Emory University, Atlanta, GA.
Heval Mohamed KelliFrom the Division of Cardiology, Emory University School of Medicine, Atlanta, GA (A.S.T., M.H., P.B.S., S.S.H., A.P.K., A.A., H.M.-K., M.T., N.G., K.C., H.A., I.H., J.H.K., P.W., L.S., V.V., A.A.Q.); and Department of Biostatistics and Bioinformatics (Y.-A.K., E.M.) and Department of Hematology and Oncology, Winship Cancer Institute (E.K.W.), Emory University, Atlanta, GA.
Matthew TopelFrom the Division of Cardiology, Emory University School of Medicine, Atlanta, GA (A.S.T., M.H., P.B.S., S.S.H., A.P.K., A.A., H.M.-K., M.T., N.G., K.C., H.A., I.H., J.H.K., P.W., L.S., V.V., A.A.Q.); and Department of Biostatistics and Bioinformatics (Y.-A.K., E.M.) and Department of Hematology and Oncology, Winship Cancer Institute (E.K.W.), Emory University, Atlanta, GA.
Nima GhasemzadehFrom the Division of Cardiology, Emory University School of Medicine, Atlanta, GA (A.S.T., M.H., P.B.S., S.S.H., A.P.K., A.A., H.M.-K., M.T., N.G., K.C., H.A., I.H., J.H.K., P.W., L.S., V.V., A.A.Q.); and Department of Biostatistics and Bioinformatics (Y.-A.K., E.M.) and Department of Hematology and Oncology, Winship Cancer Institute (E.K.W.), Emory University, Atlanta, GA.
Kaavya ChivukulaFrom the Division of Cardiology, Emory University School of Medicine, Atlanta, GA (A.S.T., M.H., P.B.S., S.S.H., A.P.K., A.A., H.M.-K., M.T., N.G., K.C., H.A., I.H., J.H.K., P.W., L.S., V.V., A.A.Q.); and Department of Biostatistics and Bioinformatics (Y.-A.K., E.M.) and Department of Hematology and Oncology, Winship Cancer Institute (E.K.W.), Emory University, Atlanta, GA.
Yi-An KoFrom the Division of Cardiology, Emory University School of Medicine, Atlanta, GA (A.S.T., M.H., P.B.S., S.S.H., A.P.K., A.A., H.M.-K., M.T., N.G., K.C., H.A., I.H., J.H.K., P.W., L.S., V.V., A.A.Q.); and Department of Biostatistics and Bioinformatics (Y.-A.K., E.M.) and Department of Hematology and Oncology, Winship Cancer Institute (E.K.W.), Emory University, Atlanta, GA.
Hiroshi AidaFrom the Division of Cardiology, Emory University School of Medicine, Atlanta, GA (A.S.T., M.H., P.B.S., S.S.H., A.P.K., A.A., H.M.-K., M.T., N.G., K.C., H.A., I.H., J.H.K., P.W., L.S., V.V., A.A.Q.); and Department of Biostatistics and Bioinformatics (Y.-A.K., E.M.) and Department of Hematology and Oncology, Winship Cancer Institute (E.K.W.), Emory University, Atlanta, GA.
Iraj HesaroiehFrom the Division of Cardiology, Emory University School of Medicine, Atlanta, GA (A.S.T., M.H., P.B.S., S.S.H., A.P.K., A.A., H.M.-K., M.T., N.G., K.C., H.A., I.H., J.H.K., P.W., L.S., V.V., A.A.Q.); and Department of Biostatistics and Bioinformatics (Y.-A.K., E.M.) and Department of Hematology and Oncology, Winship Cancer Institute (E.K.W.), Emory University, Atlanta, GA.
Ernestine MaharFrom the Division of Cardiology, Emory University School of Medicine, Atlanta, GA (A.S.T., M.H., P.B.S., S.S.H., A.P.K., A.A., H.M.-K., M.T., N.G., K.C., H.A., I.H., J.H.K., P.W., L.S., V.V., A.A.Q.); and Department of Biostatistics and Bioinformatics (Y.-A.K., E.M.) and Department of Hematology and Oncology, Winship Cancer Institute (E.K.W.), Emory University, Atlanta, GA.
Jonathan H KimFrom the Division of Cardiology, Emory University School of Medicine, Atlanta, GA (A.S.T., M.H., P.B.S., S.S.H., A.P.K., A.A., H.M.-K., M.T., N.G., K.C., H.A., I.H., J.H.K., P.W., L.S., V.V., A.A.Q.); and Department of Biostatistics and Bioinformatics (Y.-A.K., E.M.) and Department of Hematology and Oncology, Winship Cancer Institute (E.K.W.), Emory University, Atlanta, GA.
Peter WilsonFrom the Division of Cardiology, Emory University School of Medicine, Atlanta, GA (A.S.T., M.H., P.B.S., S.S.H., A.P.K., A.A., H.M.-K., M.T., N.G., K.C., H.A., I.H., J.H.K., P.W., L.S., V.V., A.A.Q.); and Department of Biostatistics and Bioinformatics (Y.-A.K., E.M.) and Department of Hematology and Oncology, Winship Cancer Institute (E.K.W.), Emory University, Atlanta, GA.
Leslee ShawFrom the Division of Cardiology, Emory University School of Medicine, Atlanta, GA (A.S.T., M.H., P.B.S., S.S.H., A.P.K., A.A., H.M.-K., M.T., N.G., K.C., H.A., I.H., J.H.K., P.W., L.S., V.V., A.A.Q.); and Department of Biostatistics and Bioinformatics (Y.-A.K., E.M.) and Department of Hematology and Oncology, Winship Cancer Institute (E.K.W.), Emory University, Atlanta, GA.
Viola VaccarinoFrom the Division of Cardiology, Emory University School of Medicine, Atlanta, GA (A.S.T., M.H., P.B.S., S.S.H., A.P.K., A.A., H.M.-K., M.T., N.G., K.C., H.A., I.H., J.H.K., P.W., L.S., V.V., A.A.Q.); and Department of Biostatistics and Bioinformatics (Y.-A.K., E.M.) and Department of Hematology and Oncology, Winship Cancer Institute (E.K.W.), Emory University, Atlanta, GA.
Edmund K WallerFrom the Division of Cardiology, Emory University School of Medicine, Atlanta, GA (A.S.T., M.H., P.B.S., S.S.H., A.P.K., A.A., H.M.-K., M.T., N.G., K.C., H.A., I.H., J.H.K., P.W., L.S., V.V., A.A.Q.); and Department of Biostatistics and Bioinformatics (Y.-A.K., E.M.) and Department of Hematology and Oncology, Winship Cancer Institute (E.K.W.), Emory University, Atlanta, GA.
Arshed A QuyyumiFrom the Division of Cardiology, Emory University School of Medicine, Atlanta, GA (A.S.T., M.H., P.B.S., S.S.H., A.P.K., A.A., H.M.-K., M.T., N.G., K.C., H.A., I.H., J.H.K., P.W., L.S., V.V., A.A.Q.); and Department of Biostatistics and Bioinformatics (Y.-A.K., E.M.) and Department of Hematology and Oncology, Winship Cancer Institute (E.K.W.), Emory University, Atlanta, GA. aquyyum@emory.edu.
Emory University · US
Funding
Serious Hazards of Transfusion & Cellular Therapies: Mechanisms and InterventionP01HL086773 · NHLBI · EMORY UNIVERSITY · PI JOSEPHSON, CASSANDRA D · 2008 to 2019
$17.9MVascular Responses During Mental StressP01HL101398 · NHLBI · EMORY UNIVERSITY · PI QUYYUMI, ARSHED A · 2010 to 2015
$11.0MMental Stress and Myocardial Ischemia after MI: Sex Differences, Mechanisms and PrognosisR01HL109413 · NHLBI · EMORY UNIVERSITY · PI VACCARINO, VIOLA · 2012 to 2023
$6.9MMultidisciplinary Research Training to Reduce Inequities in Cardiovascular HealthT32HL130025 · NHLBI · EMORY UNIVERSITY · PI Tené T Lewis, Viola Vaccarino · 2016 to 2026
$6.4MCell therapy for diabetic peripheral neurovascular complicationsDP3DK094346 · NIDDK · EMORY UNIVERSITY · PI CHENG, XIAODONG, YOON, YOUNG-SUP · 2011 to 2011
$6.1MThe role of the renin-angiotensin-endothelial pathway in ADRF1AG051633 · NIA · EMORY UNIVERSITY · PI HAJJAR, IHAB M, QUYYUMI, ARSHED A · 2015 to 2017
$6.0MAdverse effects of RBC transfusions: A unifying hypothesisR01HL095479 · NHLBI · EMORY UNIVERSITY · PI ROBACK, JOHN D · 2009 to 2017
$5.2MMetabolomics of subclinical and clinical cardiovascular diseaseP20HL113451 · NHLBI · EMORY UNIVERSITY · PI JONES, DEAN PAUL · 2012 to 2016
$4.3MPTSD and Ischemic Heart Disease Progression: A Longitudinal Twin StudyR01HL125246 · NHLBI · EMORY UNIVERSITY · PI VACCARINO, VIOLA · 2015 to 2018
$3.4MHeart Failure Clinical Trials NetworkU10HL110302 · NHLBI · EMORY UNIVERSITY · PI SMITH, ANDREW · 2012 to 2018
$2.5MGenome-wide association study of MI in CaucasiansR01HL089650 · NHLBI · DECODE GENETICS, INC. · PI GULCHER, JEFFREY R · 2007 to 2010
$2.3MBIOMARKERS OF ISCHEMIC OUTCOMES IN SYMPTOMATIC INTRACRANIAL STENOSIS (BIOSIS)R01NS064162 · NINDS · EMORY UNIVERSITY · PI FRANKEL, MICHAEL ROSS · 2010 to 2013
$1.0MNHLBI NIH HHS K23 HL127251NHLBI NIH HHS P01 HL086773NHLBI NIH HHS P01 HL101398NHLBI NIH HHS P20 HL113451NHLBI NIH HHS R01 HL089650NHLBI NIH HHS R01 HL095479NHLBI NIH HHS R01 HL109413NHLBI NIH HHS R01 HL125246NHLBI NIH HHS R56 HL126558NHLBI NIH HHS T32 HL130025NHLBI NIH HHS U10 HL110302NIA NIH HHS RF1 AG051633NIDDK NIH HHS DP3 DK094346NINDS NIH HHS R01 NS064162
Abstract
backgroundEndogenous regenerative capacity, assessed as circulating progenitor cell (PC) numbers, is an independent predictor of adverse outcomes in patients with cardiovascular disease. However, their predictive role in heart failure (HF) remains controversial. We assessed the relationship between the number of circulating PCs and the pathogenesis and severity of HF and their impact on incident HF events. METHODS AND
resultsWe recruited 2049 adults of which 651 had HF diagnosis. PCs were enumerated by flow cytometry as CD45med
conclusionsPC levels are lower in patients with HF, and lower PC counts are strongly and independently predictive of mortality. Strategies to increase PCs and exogenous stem cell therapies designed to improve regenerative capacity in HF, especially, in HF with preserved ejection fraction, need to be further explored.
Indexed as
Cell ProliferationRegenerationAgedAged, 80 and overBiomarkersChi-Square DistributionFemaleFlow CytometryGeorgiaHeart FailureHumansIncidenceLogistic ModelsMaleMiddle AgedMultivariate AnalysisBiomarkerscardiovascular outcomesCD133+CD34+CXCR4+heart failureprogenitor cellsVEGF
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.